SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalEli Lilly


Previous 10 Next 10 
From: Moonray6/1/2021 9:20:34 PM
   of 634
 
Eli Lilly gets Indian emergency use nod for Covid-19 antibody drug combination

The company said it is in talks with the Indian government and regulatory authorities to donate the drugs to help speed up access and provide more treatment options for Covid-19

Eli Lilly and Co's antibody drug combination has received an emergency use approval in India for the treatment of mild-to-moderate Covid-19, bolstering the country's arsenal of medicines to tackle a devastating second wave of the pandemic.

A combination of the U.S. drugmaker's monoclonal antibodies bamlanivimab and etesevimab has been given approval for restricted use in emergency situations in hospital settings in adults, the company's Indian unit said in an emailed statement.

More at: kathmandupost.com

o~~~ O

Share RecommendKeepReplyMark as Last Read


From: Moonray6/1/2021 9:27:56 PM
   of 634
 
Distribution of Eli Lilly COVID-19 therapy
paused in 8 states over variant concerns

For now, the FDA recommends using
Regeneron's antibody cocktail instead.

Federal health authorities have paused distribution
of Eli Lilly's monoclonal antibody cocktail in eight
tates over COVID-19 variant efficacy concerns.

The COVID-19 treatment will halt distribution in
Arizona,
alifornia,
Florida,
llinois,
Indiana,
Massachusetts,
Oregon and
Washington
"until further notice" due to variants' elevation in those
states, the U.S. Department of Health and Human
Services and Assistant Secretary for Preparedness
and Response announced in a bulletin this week.

More at: abcnews.go.com

o~~~ O

Share RecommendKeepReplyMark as Last Read


From: Moonray6/7/2021 4:05:48 PM
   of 634
 
Eli Lilly and Company The biopharmaceutical stock jumped 13%
after the approval of Biogen’s Alzheimer’s medicine by the FDA.
Eli Lilly is developing its own drug to treat Alzheimer’s.

It is quite bullish to see the P&F Objective more than 100 points higher.



o~~~ O

Share RecommendKeepReplyMark as Last Read


From: Moonray6/17/2021 1:07:24 PM
   of 634
 
Eli Lilly CEO: There will be enough COVID-19
vaccine for 'entire world' by next summer

o~~~ O

Share RecommendKeepReplyMark as Last Read


From: Moonray11/16/2021 10:42:20 PM
   of 634
 
Cramer’s lightning round: I like Eli Lilly over Biogen and Cassava Sciences

o~~~ O

Share RecommendKeepReplyMark as Last Read


From: Moonray12/11/2021 10:38:39 AM
   of 634
 
Eli Lilly and Company Expected to Earn FY2021
Earnings of $7.95 Per Share (NYSE:LLY)

o~~~ O

Share RecommendKeepReplyMark as Last Read


From: Moonray12/15/2021 10:22:09 AM
   of 634
 
Eli Lilly Pops On Boosted 2021 Outlook As Covid Brings In $2.1 Billion

o~~~ O

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Moonray who wrote (623)12/17/2021 11:51:41 AM
From: Lance Bredvold
1 Recommendation   of 634
 
I have a 270 call sold for January and during the pop this week sold another at $280 for July. While the news has been good and I have actually penciled in EPS of $8.20 (above the $7.95 speculated 2 posts ago) that puts my $270 call at a PE of nearly 33. That's more than the company has shown as a high for any of the last 10 years except 2021. Clearly $280 is just as pricy so I'm feeling pretty secure in my sales which were both for $22.00. Of course I could be wrong, but I think the odds are excellent that I'll profit from these sales.

If I had some of my shares in retirement accounts I'd probably sell as it bounced so high the other day, but I don't want to claim the huge gain on the shares in my taxable accounts at this time, so a nice 8% bonus is welcome though it also entails some tax expense.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Lance Bredvold who wrote (624)4/8/2022 9:15:38 PM
From: Lance Bredvold
   of 634
 
I don't know about anyone else, but I just don't believe prices and PE's just keep going up forever. The Jan 270 expired nicely but the July 280 is far underwater and an additional Oct 300 is also looking pretty dumb at the moment. Yet getting over $20 for each one feels pretty good for a while at least and I think I'll have the courage to sell a $320 whenever I can get $25 or so for them.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Lance Bredvold who wrote (625)4/9/2022 1:45:09 PM
From: JamesK
1 Recommendation   of 634
 
Really nice move in LLY. Moves aren't as strong but similar chart patterns in AZN MRK and big bios like AMGN VRTX REGN.

Maybe with the FED slamming on the brakes there is rotation into less economically sensitive areas.

Might feel bad losing some of your stock but be happy you're getting good prices. Sometimes I buy back the options and sell new ones in your situation.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10